Travelers from the People’s Republic of China (“China”) no longer require a negative COVID-19 test to enter the United States.  The U.S. Centers for Disease Control and Prevention (“CDC”) announced that as of March 10, 2023, travelers entering the United States by air from the People’s Republic of China and the Special Administrative Regions of Hong Kong and Macau no longer require proof of a negative COVID-19 test or evidence of COVID-19 recovery.1

The test requirement had been applicable to passengers entering the United States by air directly from China or via third-country transit and to those connecting through the United States to further destinations.2  (See GMS Flash Alert 2023-001, January 6, 2023).


Passengers flying to the U.S. from China, Hong Kong, Macau, and from designated airports, are no longer required to show a negative COVID-19 test or proof of recovery from COVID-19 prior to boarding.  The designated airports subject to the test requirement were Incheon International Airport (ICN) in Seoul, Republic of Korea; and Toronto Pearson International Airport (YYZ) and Vancouver International Airport (YVR) in Canada.  These international hubs were included due to their high numbers of travelers having originated in China.

The elimination of the test requirement reduces U.S. entry requirements and the inconvenience of completing COVID-19 testing in advance of travel.  Airlines will no longer be checking for this documentation and, so, business and leisure travel should be easier.  

Additional Information

The COVID-19 test requirement took effect on January 5, 2023, amid a surge in infections in China and as U.S. health officials expressed concerns that the government may not be reporting the true number of infections and deaths.  The CDC now reports that epidemiologic data show there is no longer a surge in COVID-19 cases in China, and the agency has not identified new variants.  The agency has determined that testing requirements are no longer necessary.

The requirement for proof of COVID-19 vaccination for all non-U.S. citizens, non-immigrants (not a U.S. citizen, U.S. national, lawful permanent resident, or traveling to the United States on an immigrant visa) entering the U.S. by air remains in place.  (See, GMS Flash Alert 2021-268, October 28, 2021).            


The elimination of the testing requirement means that previously affected travelers will no longer need to consider altering their travel plans or submit to additional steps around proving their COVID-19 negative status by means of an approved test or proof of recovery.  Employers with employees traveling from China no longer need to build in extra preparatory time to have their employees complete their testing and/or collect the necessary documents for entry.  This should help improve the ease of travel into the United States.

However, the same day the requirements were lifted by the CDC, the U.S. State Department reissued China a Level 3 Travel Advisory.3  The advisory urges Americans to reconsider travel to China, citing health risks, wrongful detention, and other potential risks.  According to the State Department’s “China Travel Advisory,” the Chinese government has not authorized the use of commonly-available COVID vaccines in mainland China, such as Moderna and Pfizer/BioNTech.  There are 13 Chinese-made vaccines, but not all of these have been approved by the U.S. FDA.

KPMG Law LLP in Canada is tracking this matter closely.  We will endeavor to keep readers of GMS Flash Alert posted on any important developments as and when they occur.

* Please note the KPMG International member firm in the United States does not provide immigration or labor law services. However, KPMG Law LLP in Canada can assist clients with U.S. immigration matters.


The information contained in this newsletter was submitted by the KPMG International member firm in Canada.


Connect with us

Stay up to date with what matters to you

Gain access to personalized content based on your interests by signing up today


GMS Flash Alert is a Global Mobility Services publication of the KPMG LLP Washington National Tax practice. The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization. KPMG International Limited is a private English company limited by guarantee and does not provide services to clients. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm. The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

We respectfully acknowledge that KPMG offices across Turtle Island (North America) are located on the traditional, treaty, and unceded territories of First Nations, Inuit and Métis peoples.

© 2024 KPMG LLP, an Ontario limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

For more detail about the structure of the KPMG global organization please visit